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In the strictest sense, the cell secretome (conditioned media) refers to the collection of
proteins that contain a signal peptide and are processed via the endoplasmic reticulum and
Golgi apparatus through the classical secretion pathway. More generally, the secretome also
encompasses proteins shed from the cell surface and intracellular proteins released through
non-classical secretion pathway or exosomes. These secreted proteins include numerous
enzymes, growth factors, cytokines and hormones or other soluble mediators. They are
fundamental in the processes of cell growth, differentiation, invasion and angiogenesis by
regulating cell-to-cell and cell-to-extracellular matrix interactions. The main aim of this review
is to provide a synopsis of findings from the analysis of the secretome taking diabetes, cancer
and neurodegenerative diseases as examples. We will also discuss the preparation of condi-
tioned media and on the main proteomic-based methodological approaches that have been
developed for the study of secreted/shed proteins.
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1 Introduction
Cell lines derived from tumours and tissues are widely used
in laboratory-based research because they reflect some of the
genotypic and phenotypic characteristics of primary tissues
under investigation. Cell lines have been extensively used,
for example, in screening studies involving drug sensitivity/
resistance of novel agents, to create tumours in the mouse
models and to investigate characteristics such as invasion
and cell division [1, 2].
Over the last number of years, many research groups
have analysed conditioned media under well-defined
experimental conditions to aid in their biomarker dis-
covery investigations (Table 1). Proteins released into
conditioned media by cultured cells are a rich source
of material for biomarker discovery experiments [3].
Certain proteins secreted from cells that enter the circula-
tory system can be exploited as molecules for screening
for the presence of disease or monitoring therapeutic
effectiveness. This technique provides a useful and less
invasive alternative to direct clinical specimen analysis
for the discovery of novel biomarkers. By using a cell-
culture model system in which the cells were grown in
serum-free media, the identification of candidate biomar-
kers through the use of proteomic analysis is enhanced
due to a lower dynamic range, spanning five or six orders of
magnitude [4] and a smaller diversity of proteins. Large data
sets of secreted or shed proteins have emerged as can-
didate biomarkers from studies of cell populations,
and many of these have been initially validated in clinical
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samples achieving high levels of sensitivity and specificity
[5–8].
Proteins identified in media conditioned by cell lines
will exit the cells through a number of different path-
ways. During the classical secretory pathway, proteins
containing an ER (endoplasmic reticulum) signal sequence,
generally at the N-terminus, are secreted in an ER/Golgi-
dependent manner [9]. During secretion through the
non-classical pathway, no signal sequences are present
and proteins are released by a variety of mechanisms,
including shedding of plasma membrane microvesicles,
direct efflux through plasma membrane transporters and
exocytosis of secretory lysosomes/exosomes [10]. Exosomes
are small (40–90 nm) membrane vesicles of endocytic
origins that harbour components of the secretome
including membrane and cytoplasmic proteins [11]. It is
also likely that alternative pathways or mechanisms are
present for proteins to exit cells that have yet to be discov-
ered (Fig. 1).
Biofluids such as plasma and serum are the ideal
samples to investigate from a biomarker discovery
perspective. They have a very high protein concentration and
act as a reservoir to concentrate signals from all tissue types
present in the body. However, only 22 proteins account for
99% of their protein content and include albumin, hapto-
globin, transferrin, immunoglobulins and complement
factors. Albumin, for example, exists at concentrations in
excess of a billion times more concentrated than many
cytokines and it is very likely that tumour-specific biomar-
kers will be present at concentrations that are much lower
[12]. Unfortunately, plasma and serum proteins are present
across a dynamic range of concentration that is likely to
span more than 12 orders of magnitude, making it extre-
mely difficult to analyse their respective proteomes
comprehensively.
Another considerable challenge for biomarker discovery
investigations in biofluids is the susceptibility of low-
abundance biomarkers to rapid degradation by endogenous
and exogenous proteinases upon release from the tumour
and also during sample processing [13]. Many low-abundant
proteins are sequestered by high-abundant circulatory
proteins which provide a certain amount of protection
from degradation but also add to the complexity of analys-
ing these candidate biomarkers. Thus, biofluid-based
approaches for biomarker discovery still represent a
significant challenge and require highly specialized tech-
nologies. Therefore, analysis of conditioned media has
many advantages over direct analysis of clinical specimens.
These advantages include the non-invasive method of
sample collection and the fact that a large number of cell
lines representing various stages/histotypes are readily
available [14]. The identification/quantification of these
secreted or shed proteins is relatively straightforward with-
out the problems that are associated with high-abundance
proteins or the dynamic range associated with many
biofluids [15, 16].
Advances in mass spectrometry (MS), label/label-free
technologies, LC systems and bioinformatic approaches
have had a tremendous influence on proteomics [17]. These
advances combined with the analysis of conditioned media
will undoubtedly facilitate the identification of candidate
Table 1. Cell lines that have been used by researchers during
proteomic investigations of the respective secretomes
Disease type Cell lines Ref.
Diabetes 3T3-L1 [48]
MIN-6 [49]
INS-1 [50]
Cancer PANC-1 [50]
NPC-TW04 [56]
CL1–0 [57]
CL1–5 [57]
MCF10AT [58]
MCF10 DCIS.com [58]
MCF 10CA cl. D [58]
SW480 [59]
SW620 [59]
PC3 [60]
LNCaP [60]
22Rv1 [60]
AsPC1 [37]
MiaPaCa2 [37]
PANC1 [37]
PT45 [37]
Neurodegenerative BV-2 [68]
B35 [68]
C6 [69]
SH-SY5Y [70]
Included is the disease type, cell line and associated reference.
Signal Peptides
20%
80%
signal peptides
coiled coil (CC)/nuclear
export signals
(NES)/nuclear
localization signal
(NLS)/Cys-Xaa-Xaa-Leu
(CAAX)/no motif
Figure 1. Analysis of conditioned media from colon cancer cell
lines. In-solution digestion and MS analysis of conditioned
media from four colon cell lines – HCT116, HT-29, SW480 and
WiDr demonstrated that 92 proteins were common to all four.
Further analysis of these 92 proteins showed that 18 of them had
a signalling peptide for processing through the classical secre-
tory pathway. As shown in the pie chart, the majority of common
proteins exited the cells by alternative pathways.
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biomarkers, initial validation in clinical samples and detec-
tion of the most promising molecules in terms of medical
utility.
2 Sample preparation
Serum-supplemented media can present analytical chal-
lenges due to the masking effects of highly abundant serum
proteins, such as bovine serum albumin (BSA), for example.
Analysis of total lysates from cultured cells frequently
results in the identification of serum proteins and this
problem is amplified when trying to investigate proteins
secreted or shed into the media. Our group has previously
looked at culturing cells in different concentrations of
serum, ranging from 0 to 10% with subsequent analysis of
secreted proteins. Even at 0.5% serum, the masking affect
of the high-abundant proteins was sufficient to make the
analysis of secreted proteins extremely difficult. Many
groups have reported on novel washing and culturing
technique for cells that considerably reduce the concentra-
tion of high-abundant supplemented serum proteins in the
secretome of these cells. Pellitteri-Hahn et al. described a
method consisting of rinsing twice with 10mL of Dulbecco’s
phosphate-buffered saline with calcium and magnesium
(DPBS) and once with 10mL of serum-free media that
showed a significant reduction in BSA peptides identified by
MS when compared with the no-rinse control cells [18]. The
percentage of contaminant BSA scans identified by MS in
the stringent wash (average, 13.2%) was much lower than
either the moderate or the no-rinse treatments (average, 35.2
and 45.2%).
In the majority of publications, cells are washed with PBS
or serum-free media or a combination of both. The
Srisomsap et al. protocol for collection of conditioned
media consisted of washing the cells with serum-free
medium two times before incubation in serum-free medium
for 24 h [19]. The Higa et al. procedure involved extensive
washing of the cells with PBS and incubated for 16 h with
serum-free Dulbecco’s-modified Eagle medium [20]. It is
clear from the literature that each group has optimized their
own specific approach for washing cells prior to incubation
with serum-free media. Certainly, there exists a fine line
between not washing the cells sufficiently, risking the
masking effects of BSA and other serum components and
washing the cells too stringently, a process that can damage
or kill the cells and lead to a release of contaminating
cytoplasmic proteins.
Other variables to consider when preparing conditioned
media samples for proteomic analysis are incubation time
and cell confluency. Both of these factors can have a
significant effect of the quality of the samples and certainly
warrant careful optimization. Some groups opt to monitor
the levels of contaminating cytosolic proteins in the media
as a measure of how conditions are affecting the quality of
the secreted protein purity in the conditioned media. For
example, Mbeunkui et al. demonstrated that the level of the
major cytosolic proteins b-actin and b-tubulin increased
significantly in the conditioned medium after 30 h or when
the cell confluency was above 70% due to cell autolysis.
Subsequent monitoring of b-actin and b-tubulin resulted in
an incubation time of 24 h and 60–70% cell confluency
being considered as the optimal incubation time and
amount of cells respectively, during conditioned medium
analysis [21]. Weng et al. monitored the relative distribution
of b-tubulin, an abundant cytosolic protein, in the
conditioned media and in the extracts of residual cells
attached on the culture dishes by Western blot analysis.
Their data show that b-tubulin was detected in the total cell
extracts but not in the conditioned media, suggesting that
the release of proteins into the conditioned media was not
caused by cell lysis and the incubation in serum-free
medium for 24 h was well controlled [22]. Therefore, careful
optimization of serum-free conditioned media collection is
an important step, however, with any protocol there is still
always the risk that contaminating abundant serum proteins
and cytosolic proteins will be identified in subsequent
investigations.
There is also a concern that culturing cells in serum-free
media for periods ranging from a few hours and many
days could impact on the phenotypic characteristics
of the cells compared with standard conditions and
therefore impinge on the nature of protein secreted
or shed into the media. Zwickl et al. demonstrated a method
involving culturing HepG2 cells using standard conditions
using methionine and cysteine-free William’s E medium
(ICN) in the presence of 35S-labelled methionine and
cysteine. Metabolic labelling of cells allows the detection of
proteins by autoradiography, when only proteins synthe-
sized by living cells during the metabolic labelling period
will be visualized [23]. More recently, Gundacker et al. also
used 35S-labelled methionine and cysteine to identify the
secreted proteins in the supernatant of cultured dendritic
cells [24].
Colzani et al. recently described the use of an LC-MS/MS-
based strategy to study serum-containing conditioned media
which combines metabolic labelling with protein equaliza-
tion using Proteominer beads [25]. An aggressive breast
cancer cell line (MDA-MB-231) grown in a standard
medium with 10% FCS was labelled with an excess of
deuterated valine (D8-Val). The obtained conditioned media
was equalized and after protein identification, the presence
of the isotope label was used to discriminate true cellular
proteins from homologous bovine ones. Quantitative
analysis was performed by comparing the secretome of
MDA-MB-231 with a less aggressive breast cancer cell line,
MCF-7. Relative quantification of validated cellular proteins
was done using spectral counting and confirmed for three
proteins LG3BP, IBP2 and FLNA using selected reaction
monitoring (SRM).
Methods for extracting proteins from conditioned media
include precipitation, ultrafiltration and lyophilization [26].
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Like all methods for purifying protein, none of these are
100% efficient and some are more suitable to certain types
of proteins if they are of primary interest. Trichloroacetic
acid/acetone precipitation is an effective approach but has
an inherent disadvantage that there is always a certain
amount of protein loss and subsequent re-solubilization of
proteins can prove troublesome. Ultrafiltration is a popular
choice when concentrating proteins in conditioned media as
this method is relatively straightforward, cost effective and
very reproducible [27].
3 Proteomic approaches for conditioned
media examination
Applying advanced proteomic-based separation and identi-
fication approaches to the investigation of media condi-
tioned by cell lines, researchers have dramatically increased
the number of candidate biomarkers identified in such
samples. Different proteomic platforms such as two-2-D
PAGE [28], 2-D DIGE [29], SELDI-TOF-MS [30], protein
arrays [31], iTRAQ [32] and MudPIT (multidimensional
protein identification technology) [33] have been used to
examine various biological samples including conditioned
medium to discover, validate and characterize disease-asso-
ciated proteins.
Stable isotope labelling technology, by both metabolic
and chemical methods, has been a very successful approach
used to profile wide-ranging proteomes in combination with
MS [34]. Perhaps, the most suitable labelling technology
when examining the secretomes of cell lines from disease
compared with normal populations or with differing levels
of invasive potential, for example, is stable isotope labelling
with amino acids in cell culture (SILAC). Cells are grown in
identical conditions, with one cell line incorporating heavy
isotopic amino acids, usually Arginine (U-13C6, 15N4) and
Lys (U-13C6) thereby taking advantage of the normal
metabolic machinery of the cell to label the proteins. The
light (natural isotope) and heavy amino acids are chemically
identical and thus co-elute upon LC-based separation. But,
since the peptides are isotopically distinct, the light- and
heavy-labelled peptides are clearly distinguishable by MS,
allowing for comparable abundance levels to be established
[7, 35].
Label-free quantitation methods are gaining in popular-
ity. The technique does not use any labelling of proteins, but
instead directly compares signal intensities between differ-
ent LC/MS runs [36, 37]. A fundamental component of
label-free quantitation is MS, which has become an essential
analytical technology in modern biological and medical
research. MS-based platforms are able to successfully
interpret the increasing number of proteins from biological
samples, such as conditioned media and together with
advanced bioinformatics programmes have the ability to
become a powerful tool for biomarker discovery and vali-
dation.
Validation of candidate biomarkers discovered through
screening of conditioned media in clinical samples is the
ultimate step when analysing the secretomes of various cell
lines, providing information on the clinical utility and
accuracy of the candidate biomarkers. ELISA, Western blot
analysis, immunohistochemistry (IHC) and multiple reac-
tion monitoring (MRM) are methods that are commonly
used to evaluate conditioned media proteins in clinical
samples. ELISA, Western blotting and IHC relay on the
availability of quality antibodies to produce consistent
valid results. ELISAs are routinely used in the clinic and
hence would be the ideal final test assay for any new
biomarkers. IHC is a valuable technique utilized to localize/
visualize protein expression in a mounted tissue section
using specific antibodies. IHC can also be scored in the
form of a semi-quantitative result, giving a general indica-
tion of the abundance levels for the specific protein being
probed [38].
Immunoassay-based validation approaches, such as
ELISA tests, are relatively easy to perform, but they are
expensive and may take a long time to develop, especially if
antibodies for the candidate biomarkers are not immediately
available. To this end, MRM, a highly specific and sensitive
MS technique has been developed that can selectively
quantify proteins within complex mixtures such as serum or
plasma samples [39]. An MRM experiment is accomplished
by specifying the parent mass of a peptide for MS/MS
fragmentation in Quadrupole 1 (Q1), and then specifically
monitoring for a single fragment ion from the parent in
Quadrupole 3 (Q3) using a triple quadrupole instrument
(QQQ). MRM delivers a unique signal (Q1–Q3 transition)
that can be monitored and quantified, using synthetic stable
isotope labeled peptide as standards, in the middle of a very
complex environment. The sensitivity of MRM is also
considerably increased when used in combination with
Stable Isotope Standards and Capture by Anti-Peptide
Antibodies (SISCAPA), a method for enriching target
peptides using anti-peptide antibodies [40].
4 Diabetes secretome analysis
Populations worldwide are currently experiencing an
epidemic of obesity with many associated health problems,
including type 2 diabetes, formerly classified as non-insulin-
dependent diabetes mellitus (NIDDM) or adult-onset
diabetes. Type 2 diabetes is a complex and heterogeneous
disease caused by both environmental and/or genetic factors
and affects more than 150 million people worldwide, a
figure that is increasing at an alarming rate [41]. Type 2
diabetes is the principal cause of blindness, kidney failure
and lower limb amputation, as well as one of the major risk
factors for heart attack and stroke [42–44].
Adipose tissue has been shown to be a primary compo-
nent of type 2 diabetes progression by establishing and
maintaining a chronic state of low-level inflammation. This
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role is mainly determined by the adipose secretome, in
particular because of the huge diversity of soluble signaling
factors that are secreted from adipose tissue [45, 46].
Therefore, a greater understanding of the adipose secretome
using proteomic-based platforms may help combat this
rapidly expanding disease.
Zvonic et al. [47] examined the secretome of primary
cultures of human subcutaneous adipose-derived stem
cells as an in vitro model of adipogenesis. Conditioned
media obtained from four individual female donors after
culture in uninduced or adipogenic-induced conditions were
compared by 2-D gel electrophoresis and MS/MS. Of
particular interest was the presence of multiple serine
protease inhibitors (serpins), a result that suggests this
protein family could play a significant role with respect to
the etiology of obesity and type 2 diabetes. Zhou et al.
recently employed cleavable isotope-coded affinity tag
(cICAT) and label-free quantitation approaches to identify
and quantify secretory factors that are differentially secreted
by 3T3-L1 adipocytes with or without insulin treatment. In
total, 317 proteins predicted or annotated as secretory
proteins were identified using this approach [48]. A total of
77 reported adipokines were quantified in this study,
such as adiponectin, cathepsin D, cystatin C, resistin and
transferrin. Overall, these results suggest that insulin
stimulation might up-regulate the glycosidases secreted
from adipocytes, and these secretory glycosidases might
modify their glycan targets in other location through
systematic circulation.
Our group has previously worked with media conditioned
by pancreatic b-cell models. Low-passage MIN-6 (mouse
insulinoma) cells respond to changes in glucose concentra-
tions, producing an approximately 5.5-fold glucose-stimulated
insulin secretion (GSIS) in response to 26.7mmol/L. After
continuous culture or high passage, this GSIS was no longer
present and thus represents an excellent model system for
investigating b-cell dysfunction (Fig. 2). Proteomic analysis of
the conditioned media revealed that secretogranin II, secreto-
granin III and transthyretin, proteins associated with secretory
granule biogenesis and were found to have substantially
increased levels in non-responsive high-passage MIN-6 b cells
and may be clinically useful for assessing b-cell function and
monitoring the effects of specific therapeutics [49].
Song et al. analysed the effects on the proteome of
pancreatic islet b cells with and without pancreatic cancer
cell-conditioned medium stimulation [50]. In this study, it
was observed that the pancreatic cancer cell-line PANC-
1-conditioned media decreased insulin secretion from rat islet
b-cell INS-1. A total of ten up-regulated proteins and five
down-regulated proteins were identified in pancreatic cancer-
conditioned media-treated b-islet cells compared with nega-
tive controls. Factors released by the pancreatic cancer cell
line into the conditioned media affected the expression levels
of HSP60, Prp19, peripherin, HMOX1 and GRP78 expres-
sion in islet b cells, establishing a link between these proteins
and pancreatic cancer-associated diabetes.
5 Cancer secretome analysis
According to GLOBOCAN, an estimated 12.7 million new
cancer cases and 7.6 million cancer deaths occurred in 2008
(http://globocan.iarc.fr/). The most frequent types of cancer
worldwide among men are lung, stomach, liver, colorectal,
oesophagus and prostate. Among women, breast, lung,
stomach, colorectal and cervical are the most prevalent [51].
Recent developments in the identification of biomarkers
may help in the early detection of cancer, aid prognosis,
predict therapeutic response and also increase our general
understanding of the underlying pathobiochemical
mechanisms of specific diseases. Generally, biomarkers are
produced by either the tumour itself or other tissues in
response to the presence of cancer, with panels of biomar-
kers likely to contain both tumour-specific and tumour non-
specific proteins [52, 53].
A large number of studies have focused on analysing the
conditioned media from cancer cells, specifically trying to
identify candidate biomarkers to potentially validate in
clinical samples. Many groups examine the secretome from
cancer cells compared with normal cells, with a particular
emphasis on detecting signatures that are unique to the
cancer cells and therefore may represent possible early
detection biomarkers. Recently, Matsumoto et al. analysed
peptides which were secreted into conditioned medium by
LCN1, a large cell neuroendocrine carcinoma cell line using
MALDI-TOF MS [54]. Two fragments of nerve growth factor
inducible (VGF) were identified in the conditioned media
and were subsequently analysed using RT-PCR analysis of
lung cancer cell lines. This data demonstrated that VGF
mRNA was expressed only in neuroendocrine carcinoma-
derived cells, a result that demonstrates the potential of VGF
as a novel serological diagnostic marker of pulmonary
neuroendocrine tumours.
Nasopharyngeal carcinoma (NPC) is a rare malignancy
arising from the epithelium of the nasopharynx. This
malignancy is uncommon in most parts of the world, but is
one of the most common cancers in Southeast Asia [55]. The
number of candidate biomarkers associated with NPC is
relatively small but recently a publication by Chang et al.
describes the identification of chloride intracellular channel
1 (CLIC1) together with 65 additional proteins found in the
conditioned media from NPC-TW04 cells [56]. Using
SignalP 3.0, SecretomeP 2.0 and TMHMM, to predict clas-
sical/non-classical pathway secretion, it was shown that 47
out of the 66 identified proteins could be secreted from NPC
cells via the various mechanisms. In particular, the plasma
levels of CLIC1 in NPC patients (N5 70) were significantly
higher than those in the healthy controls (N5 74)
(mean7SD, 16.38726.53 versus 2.3975.32 mg/mL;
p5 0.00005) when analysed using ELISA, resulting in a
sensitivity of 63% and a specificity of 77%.
Some groups compared conditioned media from cells
with invasive and non-invasive phenotypes, other focus on
identifying secreted proteins associated with drug resistance
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or metastasis. For example, Wang et al. used a combination
of results from screening the conditioned media of two
NSCLC cell lines, CL1–0 and CL1–5 with pleural effusion
proteomic data to identify 22 protein of interest [57].
Retinoblastoma-associated binding protein 46 (RbAp46) was
selected for further analysis and was found to be signifi-
cantly higher in lung cancer patients compared with healthy
controls (34.0715.7 versus 22.3716.2 ng/mL, po0.001)
and positively correlated with distal metastasis of NSCLC.
Mbeunkui et al. analysed conditioned media from a series of
isogenic breast cancer cell lines varying in aggressiveness by
MS: non-tumourigenic MCF10A, premalignant/tumouri-
genic MCF10AT, tumourigenic/locally invasive MCF10
DCIS.com and tumourigenic/metastatic MCF 10CA cl. D
[58]. Using LC-MS/MS, a-1-antichymotrypsin and galectin-
3-binding protein among others were found secreted at high
levels from MCF10 DCIS.com and MCF10CA cl. D, yet
undetected in the MCF10A and MCF10AT cell lines. These
results demonstrate that the analysis of an isogenic series of
cell lines is potentially useful for identifying prospective
markers for the early detection and aggressiveness/
progression of cancer.
Similarly, Xue et al. examined the secretome from a
primary cell line SW480 and its lymph node metastatic cell
line SW620 from the same colorectal cancer patient [59]. A
total of 145 differential proteins between SW480 and SW620
(41.5-fold change) were identified. Among them, trefoil
factor 3 (TFF3) and growth/differentiation factor 15
(GDF15), two up-regulated proteins in SW620, were further
analysed in a large cohort of clinical tissue and serum
samples. For discriminating CRC from healthy controls, the
AUC was determined to be 0.730 (95% confidence interval,
0.670–0.791) for TFF3 and 0.897 (95% confidence interval,
0.856–0.938) for GDF15. It was also observed that the high
TFF3 or GDF15 serum levels were significantly associated
with a higher histological grade, more advanced TNM stage
and the presence of distant metastases.
Sardana et al. recently examined conditioned media from
three human prostate cancer cell lines of differing origin
(PC3 (bone metastasis), LNCaP (lymph node metastasis)
and 22Rv1 (localized to prostate)) to identify secreted
proteins that could serve as novel prostate cancer biomar-
kers [60]. Based on criteria including tissue specificity,
biological function, disease association based on literature
searches and comparison of protein overlap with the
proteome of seminal plasma and serum, four novel candi-
dates, follistatin, chemokine (C-X-C motif) ligand 16,
pentraxin 3 (PTX3) and spondin 2 were validated in the
serum of patients with and without prostate cancer.
A significant difference (Kruskal–Wallis test) in sera of
Figure 2. Analysis of conditioned media from
low passage compared with high passage
MIN-6 cells. Low-passage MIN-6 (mouse
insulinoma) cells respond to changes in
glucose concentrations, producing an
approximately 5.5-fold GSIS in response to
26.7mmol/L. After continuous culture or high
passage, this GSIS was no longer present
and thus represents an excellent model
system for investigating b-cell dysfunction.
Cathepsin L was found to be 13-fold
increased in the conditioned media from low
passage compared with high passage MIN-6
cells using 2-D DIGE analysis (see graph
view). Cathepsin L (CTSL) is a ubiquitously
expressed major representative of the
papain-like family of cysteine proteinases
and in this investigation represents a candi-
date biomarker for further clinical validation
as an indicator of b-cell dysfunction. CyDye
DIGE fluor minimal dyes that consist of three
different CyDyes (Cy2, Cy3 and Cy5) were
used in this analysis. Cy3-labelled low-
passage MIN-6 cells (glucose responsive)
and Cy5-labelled high-passage MIN-6 cells
(glucose non-responsive) are shown in 3-D
view.
Proteomics 2011, 11, 794–804 799
& 2011 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.proteomics-journal.com
patients with or without CaP in all four candidates by ELISA
was observed. In addition, the correlation between PSA
levels and candidate levels in serum of patients with CaP
was significant and positive by Spearman analysis.
Analysis of conditioned media from cancer cells not only
allows researchers to identify candidate biomarkers for
the detection of cancer, but could also offer in some
instances a realistic opportunity to identify possible ther-
apeutic targets [61]. It is possible that there is some cross-
over between biomarkers of detection/monitoring and
possible drug targets, and hence it comes as no surprise that
some of the conditioned media-identified candidate
biomarkers are also mentioned in terms of therapeutic
development by many groups. An example of this is the
publication by Schiarea et al. [37]. The secretomes of four
human pancreatic ductal adenocarcinoma (PDAC) cell
lines, AsPC1, MiaPaCa2, PANC1 and PT45 were compared
with a normal counterpart, the immortalized epithelial cell
line derived from normal human pancreatic ducts, HPDE6.
This group found proteins over-expressed in all of these
PDAC cell lines including CD9, vimentin, PLOD3, SH3L3,
PCBP1 and SFRS1. This group of proteins was therefore
considered especially interesting as potential therapeutic
targets or biomarkers for pancreatic cancer. Interestingly,
other groups have proposed vimentin as a therapeutic target
in cancer, evidence that supports the identification of
potential targets through analysis of media conditioned by
cell lines [62].
6 Neurodegenerative disease secretome
analysis
Neurodegenerative diseases, such as Huntington’s, Parkin-
son’s, Alzheimer’s, Machado Joseph disease, multiple
sclerosis and Amyotrophic lateral sclerosis (ALS) represent a
subgroup of human diseases with certain features in
common, including being predominantly of adult onset.
Disease pathogenesis usually involves the progressive loss
of specific neuronal population’s characteristic of each
disease type. Millions of people worldwide suffer from
neurodegenerative disorders, illnesses that normally mani-
fest later in life. Alzheimer disease, the most prevalent of
these disorders, affects 15 million people worldwide today,
with the number of affected individuals in the United States
and Europe expected to triple by the year 2050 to 13.2
million and 16.2 million, respectively [63, 64]. Chronic
microglial activation is an important central component of
neurodegenerative diseases, with release of proin-
flammatory and neurotoxic factors such as tumour necrosis
factor-a (TNF-a), interleukin-1b (IL-1b), free radicals such as
nitric oxide (NO) and superoxide [65]. These chronic
neuroinflammatory and neurotoxic components are likely to
contribute to neuronal dysfunction and disease progression.
Given that central nervous system (CNS) tissue has very
limited, if any, regenerative capacity, it is of utmost impor-
tance to limit the damage caused by neuronal death.
Microglia, a pivotal cellular player in neuroinflammation
has therefore been the subject of much research, including
examining the secretome, in order to generate a greater
understanding of the progression of this disease group
[66–68].
To characterize secreted proteins of activated microglia,
conditioned media obtained from BV-2 mouse microglia cells
were analysed by 2-D gel electrophoresis or LC coupled with
tandem MS by Kim et al. [69]. BV-2 cells were either left
untreated or treated with lipopolysaccharide (LPS)/interferon
(IFN), to maximally activate microglia, for 4–18h under
serum-free condition. One of the proteins whose relative
abundance was increased in the conditioned media of acti-
vated microglia was cathepsin D. Further analysis demon-
strated that knockdown of cathepsin D expression in
microglia using short hairpin RNA diminished the neuro-
toxicity in a co-culture system of BV-2 microglia cells and B35
neuroblastoma, used as a model of microglia/neuron co-
culture. The author proposed from this body of study that
cathepsin D precursor protein can be a potential biomarker or
drug target for the diagnosis and treatment of neurodegen-
erative diseases that are associated with excessive microglial
activation and subsequent neurotoxic inflammation.
Jeon et al. recently screened the secretome of mixed glial
cells stimulated with LPS and IFN-g for 24 h using LC-MS/
MS [70]. Among the proteins identified by the mixed glia
secretome analysis, PTX3 secretion was most highly
induced by LPS/IFN-g stimulation. The effect of PTX3
protein on phagocytic activity of microglia was subsequently
investigated using zymosan particles with apoptotic cells
and it was observed that addition of PTX3 protein enhanced
the engulfment of zymosan particles by microglia. It was
concluded that PTX3 may serve as potential biomarkers that
help diagnose inflammatory brain disorders and predict the
drug responses.
Hur et al. examined ischemia-induced damage to the
CNS by analysing the effects of microglia (MCM)- or
astrocyte (ACM)- conditioned media obtained by chemical
ischemia on the neuronal injury in SH-SY5Y cells [71]. This
investigation showed that chemical ischemia induced
the expression and activation of microglial cytochrome
c, inflammatory cytokines, reactive oxygen species (ROS)
and NADPH oxidase in BV2 cells, resulting in neuronal cell
death in SH-SY5Y cells. Therefore, a link between the
generation of ROS and the interactions of astrocytes,
microglia and neurons during ischemic brain injury was
established.
7 Limitations of conditioned media-
based biomarker discovery
Analysis of conditioned media has proven to be a very
successful strategy for the identification of candidate
biomarkers for further validation in clinical samples.
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However, this approach does suffer from some obvious
limitations. Cell culture is an in vitro system and at a
molecular level will be different from the in vivo situation.
Ultimately, this difference will be reflected in the secretome,
making a direct correlation between conditioned media and
biofluid expressed proteins difficult.
Most human tumours, for example, are a heterogeneous
mixture of different cells with the interaction between
different cell types, resulting in a complex regulation of cell
growth, differentiation and invasion [72]. Therefore, no
single cell line can mimic this heterogeneity that is
responsible for many of the characteristics associated
with specific types of cancer. To mimic this, many groups
choose to analyse a panel of cell lines for a particular cancer
type to encapsulate the molecular diversity and subsequent
range of proteins secreted or shed into the conditioned
media [19, 22].
The interaction between the host and microenvironment
influencing tumour development and progression is absent
in 2-D culture systems together with associated morpholo-
gical characteristics. To overcome some of these limitations,
some researchers have developed more advanced systems,
including the use of co- and three-dimensional (3-D)
cultures. Analysis of the proteins secreted or shed into the
conditioned media from a co-culture system may reflect
better the interactions between the tumour cells and the
immediate microenvironment in vivo. Co-culture studies
have found that the survival and proliferation of cancer cells
are intimately linked to the soluble factors in the micro-
environment, such as epidermal growth factor (EGF) that
contribute to tumour cell proliferation, morphology, angio-
genesis and invasion. An example of the importance of this
interaction and the identification of candidate biomarkers
was a recent publication by Ween et al. [73]. This article
investigates the ovarian cancer–peritoneal interaction by
means of in vitro co-culture experiments with ovarian cancer
(OVCAR-5 and SKOV-3) and peritoneal (LP-9) cells. One of
the proteins differentially expressed in the coculture secre-
tome was identified by MALDI-TOF/TOF MS as the extra-
cellular matrix protein transforming growth factor-
b-induced protein (TGFbIp). In functional in vitro experi-
ments, treatment with recombinant TGFbIp significantly
increased the motility and invasiveness of OVCAR-5 and
SKOV-3 cells concluding that TGFbIp expressed by perito-
neal cells increases the metastatic potential of ovarian cancer
cells.
Zhong et al. postulated that stromal cells in the tumour
microenvironment alter the tumour cell secretome, includ-
ing those proteins required for tumour growth and disse-
mination [5]. To test this hypothesis, they developed an in
vitro model based on coculturing a murine K-ras mutant
lung adenocarcinoma cell line (LKR-13) with a murine lung
stromal cell (macrophage, endothelial cell or fibroblast).
They found that this co-culture system enhanced stromal
cell migration, induced endothelial tube formation,
increased LKR-13 cell proliferation and regulated the
secretion of proteins involved in angiogenesis, inflamma-
tion, cell proliferation and epithelial-to-mesenchymal
transition.
3-D culture systems are frequently used to examine the
secretome of cell lines. 3-D cultures may exhibit cellular
behaviours and morphologies similar to those seen in vivo
when compared with 2-D cultures. An example of this in the
literature is the development of a strategy for cell secretome
analysis using a hollow fiber culture (HFC) system
combined with LC-MS [56, 74, 75]. The HFC system
provides high-density 3-D cell cultures that mimic solid
tumours in vivo, and in addition, collects cell secretome with
improved efficiency. The HFC system also greatly reduces
cell lysis, which alleviates the contamination from intracel-
lular proteins.
Cell line cross-contamination can be a problem for
scientists working with cultured cells. Studies suggest that
anywhere from 15 to 20% of the time, cells used in experi-
ments have been misidentified or contaminated with
another cell line [76, 77]. Many of the problems relate to
HeLa cells, the first human cancer cell line to be established.
This is an important factor for researchers to consider, and
therefore careful quality control criteria must be adhered to
before setting out on conditioned media-based investiga-
tions.
Disease-affected cells can induce the production of
‘‘secondary’’ biomarkers in neighbouring cell types. Such
secondary biomarkers are a source of candidate molecules
that is absent when analysing the conditioned media
from cell cultures. Co-cultures are likely to reflect this
environment to a greater extent; however, the informa-
tion associated with proximal biofluids such as pancreatic
juice, saliva or nipple aspirate fluid takes in to account
both primary and secondary biomarkers [78]. Although
primary biomarkers are more disease specific, secondary
biomarkers are likely to provide additional information,
especially as part of a diagnostic panel. Biofluids are
believed to harbour all available biomarkers, including
protein fragments/peptides, modified and carrier-
bound proteins. Biofluids also exhibit different types of
active extracellular proteins produced at various stages
during the evolution of the disease. This situation
is impossible to replicate in the lab; therefore, the
emphasis is on identifying robust and uncomplicated
candidate biomarkers in cell-culture-based investigations
that have the possibility of being validated in clinical
samples.
8 Concluding remarks
Presently, there is an immediate need for easily measurable
biomarkers and associated cost-effective assays in the
clinical setting. Highly sensitive and specific biomarkers
that can aid in early detection, active monitoring of
disease, monitoring of treatment response, identification of
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patients at different stages of the disease and identifica-
tion of patients who will benefit from one treatment regime
over another are needed. Such biomarkers will have an
impact on disease diagnosis and management strategies
[79]. It is also very likely that candidate biomarkers for early
detection or monitoring could be useful as therapeutic
targets.
It is clear that single biomarkers are unlikely to provide
the sensitivity and specificity needed for screening the
general population, assessing the effectiveness of treatment
or monitoring relapse, given the substantial heterogeneity.
In the future, panels of biomarkers are likely to be used in
the clinic because of increased levels of overall accuracy.
Members of these diagnostic panels are likely to be discov-
ered in different biological samples using various experi-
mental approaches. Therefore, the secretome including
proteins released through various mechanisms such as
classical secretion, non-classical secretory pathway and
release through exosomes will play a central role in identi-
fying such panel elements.
The authors have declared no conflict of interest.
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